Cytogen Corp. has provided Endotronics Inc.'s first commercial biotechnology contract for several trial batches of monoclonal antibodies for use in clinical programs, Endotronics said. Endotronics (NASDAQ:ENDO), a cell culture production-scale instrument company based in Minneapolis, also announced it has filed a type I drug master file with FDA that described the procedures, equipment and facilities it has to offer contract manufacture of clinical grade biopharmaceuticals. This filing is one
Viratek Inc. completed its public offering of 1.375 units at $7.75 per unit. The units consist of one share of Viratek common stock and one common stock purchase warrant, and are traded on the American Stock Exchange (ASE:VRAE). There were 14.6 million shares of common stock outstanding prior to the offer. Net proceeds from the offering, estimated at about $9 million, will be used to complete Phase III clinical trials and related project costs to evaluate the company's anti-viral compound
Alpha 1 Biomedicals Inc. is placing a call on its class B warrants, the Bethesda, Md., company announced Friday. The warrants, issued in July 1991, became callable once the common stock traded at an average share price greater than $15 during 20 consecutive days, R. J. Lanham, vice president of finance, told BioWorld. Holders may exercise the warrants until March 2, and may purchase one share of common stock and one class C warrant upon payment of a $12 exercise price. The company will redeem
An infection-fighting agent that is not an antibiotic has passed its Phase II clinical trials with high marks, according to results reported in San Diego over the weekend. Speaking Saturday at the Second International Congress on Biological Response Modifiers, Gary R. Ostroff, vice-president of research at Alpha-Beta Technology Inc., told some 400 clinicians that Betafectin, the company's anti-infective carbohydrate, had shielded 47 percent of post-surgery patients from infection, while 100
The French antisense company Genset announced Friday it has started clinical trials with two antisense drugs for chronic myelogenous leukemia. The trials, conducted under a French request for compassionate treatment, involve compounds GT1102 and GT1106. In the first stage, Genset and its collaborators are testing the activity of these compounds for bone-marrow purging in tissue culture. In a second stage, some patients at a blast crisis stage will be selected for autologous bone marrow
The preliminary results of a multicenter Phase II clinical trial on the biological response modifier Virulizin indicated that the product "provides survival and quality-of-life benefits" to patients with advanced malignant melanoma. Jaime de la Garza of the Mexican National Cancer Institute, who coordinated the Mexican trials on Imutec Corp.'s compound, presented the results on Virulizin last Friday at the Second International Congress on Biological Response Modifiers in San Diego. Virulizin
European Patent Disclosures Published Jan. 7, 13 (EPO), Jan. 7 (WO), Jan. 6 (GB) Abbott Laboratories Ligase chain WO 93/00447 Abbott Park, Ill. reaction (LCR) "Gap-filling" LCR amplifies target nucleic acids. Probes with specific sequences claimed for a number of pathogens. Advanced Tech. (Cambridge) Plant starch EPO 521 621 Cambridge, England production Plant cell transformed with chimeric gene comprising antisense coding sequence alters starch constitution, but not total output. American
A new Colorado biotechnology company based upon the commercial potential of "superantigen" research has saved several months in start-up time by moving into existing laboratory space of the Colorado Bio/Medical Venture Center in Lakewood, company directors said Friday. The newly formed company, Supragen, was started with $1 million initial funding from the venture capital firm E.M. Warburg, Pincus & Co., which also funded the Colorado companies Synergen Inc. and NeXagen. Supragen is subleasing
Sepracor Inc. announced Thursday that it has introduced a new chromatographic approach, termed HyperDiffusion Chromatography, to the commercial-scale production of biopharmaceuticals. The Marlborough, Mass. company's HyperDiffusion chromatography "is designed to combine the high flow advantages of perfusive materials with the high protein binding capability of soft gels through the use of Sepracor's proprietary media HyperD. HyperD media consist of a unique rigid structure with gel-filled pores
Organogenesis Inc. announced Friday that clinical trials on its full-thickness living skin equivalent Graftskin have demonstrated positive preliminary results for three medical applications: for treating chronic wounds resulting from venous stasis, for replacing skin lost to dermatological surgery, and for treating burn wounds. In all three trials on 65 patients, Graftskin did not elicit an immune response, the product had an excellent safety profile and it enhanced wound healing or graft take
Applied Biosystems Inc. (NASDAQ:ABIO) has been granted an exclusive worldwide license that should allow it to provide the cattle industry with the first standardized, automated DNA typing analysis. The Foster City, Calif., supplier of automated DNA analysis systems is licensing polymorphic microsatellie markers from Genmark Inc., a leader in developing a bovine genetic map and identifying commercially relevent traits, such as milk production potential. (c) 1997 American Health Consultants. All
Advanced Tissue Sciences Inc. (ATS) has taken its first step to license its living skin replacement in Japan, with a preliminary agreement with Mitsubishi Kasei Corp. Mitsubishi Kasei has a proven track record with biopharmaceuticals in Japan, said Jim Linton, ATS's manager of program administration. The diversified global chemical company is currently distributing tissue plasminogen activator (t-PA) and a hepatitis B vaccine it licensed from Genentech Inc. of South San Francisco, Calif
Centocor Inc. said Thursday it will resume a placebo-controlled trial of HA-1A/Centoxin in children with fulminant meningococcemia under a U.S. investigational new drug (IND) application. Enrollment of patients with this gram-negative infection had been suspended on Jan. 18. The Safety and Efficacy Monitoring Committee for this trial has recommended resuming the study after reviewing the data from interim analyses in both this trial and a separate trial that was investigating the utility of HA
DNA Plan Technology Corp. announced Thursday that its diagnostics unit, Agri-Diagnositics Associates (ADA), has signed a letter of intent to sell its Reveal and Alert plant disease detection product lines to Neogen Corp. of Lansing, Mich. These products are used to detect plant diseases that affect golf courses, and greenhouse and nursery crops. The sale follows the company's strategy, initiated in November, to "exit certain businesses that are no longer part of our strategic focus," said
President Clinton would be hard-pressed to have picked a better science adviser than Jack Gibbons, who has been director of the Congressional Office of Technology Assessment (OTA) for the past 13 years. Gibbons, who Clinton tabbed at the end of December, is lauded on Capitol Hill from both sides of the aisle, as well as from within the biotechnology community and by former colleagues at OTA. The praise is effusive from all quarters for his knowledge, integrity, ability to communicate technology
Liposome Technology Inc. said Thursday that it has begun its double-blind Phase III clinical trial of Amphocil in aspergillosis patients. The Menlo Park, Calif., company (NASDAQ:LTIZ) is conducting the trial in the U.S. and Europe to compare Amphocil with standard amphotericin B therapy. Aspergillosis is one of the most difficult to treat of the systemic fungal infections. Amphotericin B, administered by intravenous injection, is indicated for patients with progressive, potentially fatal
Vestar Inc. of San Dimas, Calif., named to its board of directors James D. Watkins, former secretary of energy under the Bush administration. Vestar also named Roger Crossley, president and chief executive officer, to the additional post of chairman of the board. BioCryst Pharmaceuticals Inc. of Birmingham, Ala., named Ronald E. Gray chief financial officer. Gray was chief financial officer and secretary of Image Data Corp. Michael Hitchcock was named director for project management at Gilead
Ribozyme Pharmaceuticals Inc. (RPI) announced Thursday that it has just raised $12 million in a second round of private financing. The financing group included all the firms that participated in Ribozyme's first round of financing, which brought in $6 million last February: Bio Holdings, Morgenthaler Ventures, Venrock Associates, CW Group and Advent International, as well as J.H. Whitney (which led the current round), Oak Investments, Grace Horn Ventures, JAFCO, U.S. Biochemical Corp. and other
Magainin Pharmaceuticals Inc. announced Thursday that it has completed a public offering of 3.5 million shares of common stock (NASDAQ:MAGN) at $6 per share. All of the shares will be sold by the company. The offering is being managed by Hambrecht & Quist Inc., Smith Barney, Harris Upham & Co. Inc. and S. G. Warburg Securities. After the offering, there are 12.2 million fully diluted shares outstanding, the company told BioWorld. The Plymouth Meeting, Pa., biopharmaceutical company researches
InnoVet Inc. announced that it has submitted a product license application (PLA) to the U.S. Department of Agriculture for approval to market its IVET 629 immune stimulant for treating chronic respiratory disease in horses. About 30 percent of the horses in the U.S. -- or 2 million -- experience one or more episodes of respiratory disease each year. That market, according to Jesse Houdeshell, InnoVet's president, is currently served by two products. But InnoVet's IVET 629, trade-named Stimugen
Cytogen Corp. has provided Endotronics Inc.'s first commercial biotechnology contract for several trial batches of monoclonal antibodies for use in clinical programs, Endotronics said. Endotronics (NASDAQ:ENDO), a cell culture production-scale instrument company based in Minneapolis, also announced it has filed a type I drug master file with FDA that described the procedures, equipment and facilities it has to offer contract manufacture of clinical grade biopharmaceuticals. This filing is one